Updated November 7, 2026 | v7.4

Renal updates by clinical finding

Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.

Search all 1,215 records | Source cautions

Dose or interval change

Tinidazole (Tindamax), oral tablet

Renal measure: Creatinine clearance (CrCl), mL/min
Renal action or finding: Severe renal impairment alone does not require dose reduction. When tinidazole is taken before HD on the same day, give another half of the recommended dose after the session.
Limits and monitoring: The supplement applies to the timing described. The severe-impairment PK study used CrCl below 22 mL/min.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 9, posted Dec 28, 2021 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Dose or interval change

Tolterodine tartrate (Detrol), oral tablet

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: For significant renal impairment the immediate-release tolterodine regimen is 1 mg twice daily.
Limits and monitoring: Verify immediate-release tablets. The ER capsule has different dosing instructions.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 5, posted Feb 03, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Dose or interval change

Topiramate (Topamax), oral tablet

Renal measure: CrCl normalized to 1.73 m2, mL/min/1.73 m2
Renal action or finding: When indexed CrCl is below 70 mL/min/1.73 m2, use half the usual adult dose for the indication.
Limits and monitoring: Hemodialysis may require a supplement based on session duration, dialysis clearance, and residual kidney function.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 31, posted Oct 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Dose or interval change

Topiramate (Trokendi XR), oral extended-release capsule

Renal measure: CrCl normalized to 1.73 m2, mL/min/1.73 m2
Renal action or finding: At CrCl below 70 mL/min/1.73 m2 use half the usual adult extended-release topiramate dose for the indication.
Limits and monitoring: Hemodialysis can remove topiramate. Consult the dialysis section for session-specific considerations.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 31, posted Oct 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Dose or interval change

Vigabatrin (Sabril), oral tablet

Renal measure: Creatinine clearance (CrCl), mL/min
Renal action or finding: For adults and children age 2 years or older, reduce the usual dose by 25% at CrCl above 50 through 80, by 50% above 30 through 50, and by 75% above 10 through 30 mL/min.
Limits and monitoring: Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 40, posted Dec 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Dose or interval change

Zidovudine (Retrovir IV), adult IV infusion only

Renal measure: Cockcroft-Gault CrCl, mL/min
Renal action or finding: For adults maintained on HD or PD, or with Cockcroft-Gault CrCl below 15 mL/min, the IV zidovudine equivalent of the renal-adjusted oral regimen is approximately 1 mg/kg every 6-8 hours.
Limits and monitoring: Confirm route and weight. The source distinguishes the IV equivalent from the oral 100 mg dose.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 33, posted Oct 08, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

RX coverage and remaining workload | Previous 90-product roundup